***Background.*** Empiric antimicrobials for critically-ill patients routinely include combination therapy for patients at risk for infection from *P. aeruginosa*. In 2013, in vitro susceptibility to anti-pseudomonal beta-lactams, ciprofloxacin and tobramycin among ICU isolates at of *P. aeruginosa* was \< 85%, 70% and \>90%, respectively. This prompted the question of whether an aminoglycoside should routinely be administered with an anti-pseudomonal beta-lactam antibiotic as empiric therapy in ICU patients.

***Methods.*** The study aimed to describe the epidemiology and patient outcomes of infection due to *P. aeruginosa* with in vitro resistance to at least one anti-pseudomonal beta-lactam agent. A retrospective study of patients admitted to an ICU between January 1 and December 31, 2013 with at least 1 isolate of *P. aeruginosa* with in vitro resistance to at least one of the anti-pseudomonal beta-lactam agents was completed.

***Results.*** Overall, 61 ICU patients out of 15, 311 ICU admissions (0.4%) had 100 isolates with resistance to at least one anti-pseudomonal beta-lactam agent. Nineteen (31.2%) had \>1 isolate recovered during the calendar year and 38 (62.3%) had structural respiratory tract changes and/or depressed CNS function that likely predisposed to *P. aeruginosa* colonization or infection. Sepsis was listed as a diagnosis in 10 patients.

Based on empiric choices of therapy, 21 patients had a "mismatch" in therapy, based on drug administration and in vitro susceptibility results.

Twenty-one (34.4%) of 61 patients died during the hospitalization or shortly thereafter. Of these, 8 (38.1%) had received mismatched therapy. In only one case, death was possibly related to mismatched therapy.

***Conclusion.*** The results of this study suggest that despite the concerning decrease in susceptibility of both beta-lactams and quinolones to *P. aeruginosa,* the recovery of beta-lactam resistant *P. aeruginosa* in our ICU cohort was uncommon and did not result in a significant worsening of patient outcomes. Therefore, even with decrease in susceptibilities**,** routine use of empiric combination therapy that includes an aminoglycoside does not seem warranted at this time.
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